EUVIMEDEUVIMED entdecken
Crossref

NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma

Liuting Chen, Feifei Cheng, Yung-Hsing Huang, Yutong Wang, Jin He, Jiaqi Liu, Zhiming Wang, Pei Lin, Yihui Fan, Li Bao, Qing Yi, Jing Yang

Drug Resistance Updates · 2026-09 · 88 · 101436

DOI: 10.1016/j.drup.2026.101436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-09. Verfasst von Liuting Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas 77030, USA; Department of Path…. Hauptthemen laut MEDLINE: Multiple Myeloma, Proteasome Inhibitors, Drug Resistance, Neoplasm, Endosomes. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, Blood Cancer United, International Myeloma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Proteasome inhibitors (PIs) play a central role in multiple myeloma (MM) therapy; however, a substantial proportion of patients fail to achieve durable responses, resulting in early disease progression and limited long-term clinical benefit. This paper aims to understand the molecular mechanisms that constrain PI efficacy and drive resistance and explore a novel strategy for improving therapeutic outcomes in MM. METHODS: By integrative analysis of multiple publicly available transcriptomic datasets from large MM patient cohorts, we identified sodium-hydrogen exchanger 6 (NHE6), encoded by SLC9A6. This gene emerged as a candidate gene associated with resistance to PI-based therapy. Functional studies were performed using patient-derived primary MM cells, PI-resistant MM cell lines, and preclinical mouse models. RESULTS: NHE6 is highly expressed in MM cells with further upregulation in PI-nonresponsive disease. Elevated NHE6 expression is associated with reduced progression-free and overall survival. We demonstrate that NHE6 promotes acidification in the endosomal lumen, thereby facilitating early-to-late endosomal maturation and enhancing autophagic flux in MM cells. This process in turn attenuates PI-induced tumor cell apoptotic death. Consistent with this mechanism, genetic ablation or pharmacologic inhibition of NHE6 disrupted endosomal maturation, impaired autophagy, and markedly increased sensitivity to bortezomib and carfilzomib in vitro and in vivo PI-resistant models. CONCLUSIONS: These findings identify an NHE6-mediated endosomal-autophagy axis as a previously unrecognized mechanism of PI resistance in MM. Targeting NHE6 represents a promising upstream strategy to restore apoptotic responses to PI-based therapies and improve therapeutic outcomes in refractory MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaProteasome InhibitorsDrug Resistance, NeoplasmEndosomesSodium-Hydrogen ExchangersHumansAnimalsMiceAutophagyCell Line, TumorXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticAntineoplastic AgentsBortezomib

Stichwörter der Autor:innen

ApoptosisAutophagyEndosome maturationMultiple myelomaNHE6Proteasome inhibitorTherapeutic resistance

Substanzen

Proteasome InhibitorsSodium-Hydrogen ExchangersAntineoplastic AgentsBortezomib

Autor:innen und Institutionen

  • Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas 77030, USA; Department of Pathogenic Biology, School of Medicine, Nantong University, Jiangsu 226001…
  • Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas 77030, USA.
  • Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas 77030, USA; Department of Hematology, Jishuitan Hospital, Capital Medical University, Beijing 100035…
  • Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Department of Pathogenic Biology, School of Medicine, Nantong University, Jiangsu 226001, China.
  • Department of Hematology, Jishuitan Hospital, Capital Medical University, Beijing 100035, China.

Förderung

  • Cancer Prevention and Research Institute of Texas
  • Blood Cancer United
  • International Myeloma Society
  • American Cancer Society Inc

Zitieren

APA

Chen, L., Cheng, F., Huang, Y. H., Wang, Y., He, J., Liu, J., Wang, Z., Lin, P., Fan, Y., Bao, L., Yi, Q., & Yang, J. (2026). NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma. Drug Resistance Updates, 88, 101436. https://doi.org/10.1016/j.drup.2026.101436

Vancouver

Chen L, Cheng F, Huang YH, Wang Y, He J, Liu J, et al. NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma. Drug Resistance Updates. 2026;88:101436. doi:10.1016/j.drup.2026.101436

BibTeX
@article{Chen2026,
  author = {Chen, Liuting and Cheng, Feifei and Huang, Yung-Hsing and Wang, Yutong and He, Jin and Liu, Jiaqi and Wang, Zhiming and Lin, Pei and Fan, Yihui and Bao, Li and Yi, Qing and Yang, Jing},
  title = {NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {88},
  pages = {101436},
  doi = {10.1016/j.drup.2026.101436}
}
Kostenlos starten →